TP53 mutation and survival in aggressive B cell lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30838
Abstract: TP53 is mutated in 20–25% of aggressive B‐cell lymphoma (B‐NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current… read more here.
Keywords: tp53 mutation; aggressive cell; tp53; tp53 mutations ... See more keywords
Mutation of the TP53 gene in acute lymphoblastic leukemia does not affect survival outcomes after haploidentical hematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34323
Abstract: Previous studies have demonstrated that TP53 mutation is correlated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). Few studies have investigated the impact of TP53 mutation in ALL patients after haploidentical… read more here.
Keywords: cell; year; survival; acute lymphoblastic ... See more keywords
The Long-To-Short-Axis Ratio and Multifocality are Associated With TP53 Mutation Status in Surgically Resected Hepatocellular Carcinomas.
Sign Up to like & getrecommendations! Published in 2018 at "Academic radiology"
DOI: 10.1016/j.acra.2018.04.021
Abstract: RATIONALE AND OBJECTIVES In hepatocellular carcinoma (HCC), the tumor protein 53 (TP53) gene is frequently mutated and the mutations have been associated with poor prognosis. We aim to retrospectively identify the relationship between TP53 mutation… read more here.
Keywords: tp53 mutation; mutation status; ratio; multifocality ... See more keywords
Constitutional mosaicism of a de novo TP53 mutation in a patient with bilateral choroid plexus carcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer genetics"
DOI: 10.1016/j.cancergen.2017.07.001
Abstract: Choroid plexus tumors (CPT) constitute 2%-5% of all pediatric brain tumors and include high grade choroid plexus carcinoma (CPC). About 40% of CPC patients harbor germline TP53 mutations, associated with diminished survival rates. However, the… read more here.
Keywords: choroid plexus; tp53 mutation; mosaicism; novo tp53 ... See more keywords
The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Genes and Diseases"
DOI: 10.1016/j.gendis.2020.04.001
Abstract: Abstract TP53 mutations was reported to be correlated to the efficacy of program death-1 (PD-1) and program death ligand-1 (PD-L1). The role of co-mutations of TP53 with other recurrently mutated genes in outcome of anti-PD-(L)1… read more here.
Keywords: mutation 240; tp53 mutation; nsclc patients; longer pfs ... See more keywords
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0831-z
Abstract: Despite high remission rates after CD19 CAR T-cell therapy in patients with refractory or relapsed B acute lymphoblastic leukemia (r/r B-ALL), relapses were commonly observed [1–4]. To improve long-term disease-free survival (DFS), our and other… read more here.
Keywords: cd19; tp53 mutation; therapy; car ... See more keywords
Pan‐Cancer Integrative Analyses Reveal the Crosstalk Between the Intratumoral Microbiome, TP53 Mutation and Tumour Microenvironment
Sign Up to like & getrecommendations! Published in 2025 at "IET Systems Biology"
DOI: 10.1049/syb2.70035
Abstract: ABSTRACT Accumulating evidence suggests that the TP53 mutation, intratumoral microbiome, and tumour microenvironment (TME) are closely linked to tumourigenesis, yet the biological mechanisms underlying these connections remain unclear. To explore this, we collected multi‐omics data—including… read more here.
Keywords: tumour microenvironment; cancer; tp53 mutation; intratumoral microbiome ... See more keywords
Elucidating the immune landscape and potential prognostic model in acute myeloid leukemia with TP53 mutation
Sign Up to like & getrecommendations! Published in 2024 at "Hematology"
DOI: 10.1080/16078454.2024.2400620
Abstract: ABSTRACT Objectives The TP53 mutation, a prevalent tumor suppressor gene alteration, is linked to chemotherapy resistance, increased relapse rates and diminished overall survival (OS) in acute myeloid leukemia (AML) patients. Methods In this study, we… read more here.
Keywords: tp53 mutation; myeloid leukemia; tp53; acute myeloid ... See more keywords
Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review
Sign Up to like & getrecommendations! Published in 2024 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001594
Abstract: Shwachman-Diamond syndrome (SDS) is an autosomal recessive genetic disease, which is prone to transform into myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). TP53 mutation is a driving factor involved in the transformation of SDS… read more here.
Keywords: aml tp53; sds; tp53 mutation; combined venetoclax ... See more keywords
Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi‐omics analysis
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Science"
DOI: 10.1111/cas.16302
Abstract: Mutations of KRAS, CDKN2A, TP53, and SMAD4 are the four major driver genes for pancreatic ductal adenocarcinoma (PDAC), of which mutations of KRAS and TP53 are the most frequently recognized. However, molecular‐targeted therapies for mutations… read more here.
Keywords: tpi1 potential; tp53 mutation; mutation; therapeutic target ... See more keywords
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre
Sign Up to like & getrecommendations! Published in 2022 at "Internal Medicine Journal"
DOI: 10.1111/imj.15851
Abstract: The Victorian Comprehensive Cancer Centre consortium sponsored representative working groups to review the role of TP53 mutation testing in the management of newly diagnosed mantle cell lymphoma (MCL). For many patients with this diagnosis, MCL… read more here.
Keywords: newly diagnosed; tp53; tp53 mutation; cell lymphoma ... See more keywords